FDA Expectations for Allogeneic iPSC-Derived Cell Therapies: Tumorigenicity, Cell Banking, CMC, and Comparability

FDA expectations for allogeneic iPSC-derived cell therapies: tumorigenicity, cell banking, CMC and comparability

Allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) sit at the intersection of two things FDA already regulates heavily: pluripotent starting material with intrinsic tumor-forming potential, and an "off-the-shelf" banked manufacturing model built for scale. There is no approved BLA for an allogeneic iPSC-derived product; the closest CBER precedent in the licensed-biologics record is an allogeneic hematopoietic stem/progenitor cell and T-cell product (TREGZI, BLA 125868), which is not iPSC-derived and does not itself establish iPSC-specific CMC or tumorigenicity expectations ⁷⁴. In practice, FDA reviews these programs at the IND stage against its existing cell and gene therapy (CGT) guidance framework, applied with a risk-based, product-specific lens. The sections below pull together what that framework requires across tumorigenicity, banking, CMC and comparability.

The guidance framework FDA applies

No single guidance is written solely for iPSC-derived therapies. Instead, several CGT guidances combine to define expectations:

Preclinical Assessment of Investigational Cellular and Gene Therapy Products for animal models, biodistribution and tumorigenicity/toxicology design ²⁴²⁵²⁶³⁶⁴⁶.
Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products for the tumorigenicity rationale and iPSC characterization expectations ⁹⁵¹⁵⁴.
Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products (draft), the most iPSC-relevant document on genomic integrity, whole genome sequencing and tumorigenicity of expanded allogeneic banks ¹¹⁶⁹⁶¹⁵⁷¹⁴⁷¹⁵⁸¹⁵⁹¹⁴⁵.
Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy INDs and the older Content and Review of CMC Information for Human Somatic Cell Therapy INDs for drug substance/drug product definition, controls and release testing ¹¹⁸¹⁴⁴¹⁰⁹¹³⁸¹⁰⁰¹⁴⁸.
Potency Assurance for Cellular and Gene Therapy Products and Potency Tests for Cellular and Gene Therapy Products for potency strategy ⁵¹⁵⁹⁵².
Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products for lifecycle comparability ⁷⁵⁶⁹⁷⁹.
ICH Q5A(R2), Q5D and Q14 for viral safety, cell-substrate characterization and analytical-procedure/bridging expectations ¹²⁹¹³¹¹¹⁹¹²⁷⁸³⁹⁰.
Donor-eligibility rules under 21 CFR Part 1271 for allogeneic source material ⁴⁸⁹.

Because iPSCs are a continuously proliferating, pluripotent cell substrate that is banked and expanded, the "Safety Testing of Human Allogeneic Cells" draft and the cell-substrate guidances (Q5D, viral vaccine cell-substrate guidance) carry disproportionate weight for this modality ⁹⁶¹⁵⁷¹¹⁴¹¹⁹.

Tumorigenicity assessment

Tumorigenicity is the defining preclinical risk for this class. FDA's stated rationale is that pluripotent stem cell-derived products carry potential for aberrant proliferation, aberrant differentiation and teratoma formation, and tumorigenicity studies are therefore generally recommended for pluripotent/iPSC-derived products ⁹⁵.

Key expectations from the FAQ and preclinical guidances:

Study placement. Tumorigenicity can be evaluated in a dedicated study or built into a nonclinical safety/toxicology study ⁹⁵.
Model selection. The animal species/strain should be permissive to engraftment and long-term survival of the product following the intended clinical route of administration ⁹⁵. More broadly, the preclinical program should use a species/model that shows a biological response similar to humans and should be individualized to the product ²⁴²⁵²⁶.
Powering and duration. Enough animals should be used to detect low-frequency events and to reach scheduled sacrifice for meaningful interpretation; study duration and sacrifice timepoints should be driven by the product's in vivo distribution and persistence profile ⁹⁵.
Tumor attribution. If tumors arise, the sponsor should determine whether they are host- or donor-derived ⁹⁵.
Justification for omission. If a sponsor believes a tumorigenicity study is unnecessary, a scientific justification with supporting data is expected in the submission ⁹⁵.

An important nuance for the banked substrate itself: in the "Safety Testing of Human Allogeneic Cells" draft, FDA notes that cancer cell lines and pluripotent cell lines are generally not tested for tumorigenicity as a cell-bank safety endpoint, because they are inherently expected to form tumors ⁹⁶. In other words, the tumorigenicity question moves downstream to the differentiated final product and to residual undifferentiated cells, rather than being answered by testing the iPSC bank. Tumorigenicity testing may draw on MCB cells when the final-product cells are phenotypically similar to the bank, and may not be necessary where comparability to cells already characterized in preclinical studies can be shown; testing of irradiated cells is not recommended ⁹⁶.

Residual undifferentiated pluripotent cells in an otherwise differentiated product are the practical control point that flows from this rationale ⁹⁵. FDA's published CGT guidance does not set a numeric residual-cell acceptance limit or a prescribed assay; that expectation is currently product-specific and is best confirmed with the review division rather than read off a guidance, which is a natural follow-up for any specific program.

Genomic integrity and whole genome sequencing

Genomic and genetic stability is treated as part of the overall tumorigenicity and safety risk assessment ⁹⁵. The "Safety Testing of Human Allogeneic Cells Expanded" draft is the most concrete source and is directly applicable to expanded iPSC banks and their genetically modified derivatives:

Perform whole genome sequencing (WGS) and analysis on cell banks of continuous cell lines and genome-edited cells ¹⁵⁷.
For continuous cell lines contributing cells to the final product, WGS at at least 50X read depth, compared against a database of cancer-associated mutations, with justification of method and conclusions ¹⁵⁷.
For highly expanded clones of genetically modified cells, WGS at at least 50X read depth to identify off-target editing, on-target editing outcomes, vector integration events and mutations of concern ¹⁵⁷; for cells that are not extensively expanded, targeted sequencing is recommended instead ¹⁵⁸.
For highly expanded primary cells, WGS or cytogenetic testing for genome integrity, with WGS the recommended method ¹⁵⁷.
Cytogenetic (karyotype) testing is not recommended for continuous cell lines or highly expanded genetically modified cells that have already undergone the recommended WGS ⁹⁶.

For cell substrates expanded to or beyond the end-of-production passage, FDA also expects demonstration of stability of key characteristics: growth characteristics, tumorigenic phenotype, endogenous virus expression, stability of inserted/engineered genes, and genetic stability ¹²³.

Cell banking

The allogeneic, banked model is where iPSC therapies most resemble a classical biologic, and FDA's cell-substrate expectations apply.

Two-tiered banking. A Master Cell Bank (MCB) and Working Cell Bank (WCB) system is expected. The MCB should be extensively characterized; the WCB may be tested more narrowly, focused on adventitious agents introduced during expansion from the MCB. At least one bank must be characterized extensively, and where the MCB is not thoroughly characterized FDA may request thorough characterization of each WCB lot ¹¹⁴¹¹⁵. WCB qualification is generally less extensive but should include at least sterility, mycoplasma, identity and in vitro adventitious agent testing ¹²¹.
Derivation and passage control. Banks should be derived and banked under defined culture conditions with clear description of design and derivation; production passage/population-doubling limits should not exceed limits justified by cell-substrate characterization ¹¹⁴¹¹⁹.
Storage and stability. Storage conditions must be shown suitable for long-term stability (recovery/viability data), with redundant storage locations and controlled access/records ¹¹⁵.
Allogeneic-specific concerns. FDA recommends qualifying allogeneic master and working banks similarly to banks used for viral-vector production, with particular attention to adventitious agents that could be introduced during banking from human, bovine, porcine, feeder-cell or other animal-derived reagents; small-scale allogeneic banks may warrant discussion with FDA ¹²².
Viral safety. Consistent with ICH Q5A(R2), cell-line qualification testing should cover the MCB, WCB and cells at the limit of in vitro cell age, including retrovirus and endogenous virus testing and in vitro/NGS adventitious virus assays as appropriate ¹²⁹¹³¹.
iPSC-specific characterization. For iPSC-derived products, the reprogramming method used to induce pluripotency, the pluripotent state/pluripotency, and cell banking are all expected elements of product characterization and the CMC control strategy, developed with a risk-based approach ¹⁵⁴.

Donor eligibility for the allogeneic source

Because the starting cells are allogeneic, the donor of the source material is regulated as a human cell/tissue product (HCT/P) under 21 CFR Part 1271, Subpart C, requiring a donor eligibility determination based on both screening and testing ⁴⁸. FDA expects:

Screening showing the donor is free from risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, and free from xenotransplantation-associated risks ⁴.
Testing with negative/nonreactive results for relevant communicable disease agents (with the syphilis exception), using FDA-licensed, approved or cleared donor-screening tests per the manufacturer's instructions when available ⁹²⁰.
A responsible person documenting the determination, and established procedures for screening, testing and eligibility ⁹²¹.
Specimen-timing rules for living donors (at recovery or within 7 days before/after; up to 30 days before for certain HPC allogeneic donations), and testing of the birth mother for donors one month of age or younger ².

An incomplete determination generally bars use of the HCT/P absent a defined exception such as urgent medical need ⁹⁵.

CMC

FDA's CMC expectations track the standard drug substance/drug product (DS/DP) construct, applied to a living, banked product ¹⁴⁴¹³⁸.

Define DS and DP. For gene therapy INDs, CMC information should describe the DS and DP and the safety/quality of human- and animal-derived materials used in manufacturing ¹⁴⁴. For somatic cell therapy INDs, FDA expects detailed descriptions of cell source, collection, processing, ancillary materials, formulation, test methods, release criteria, storage/shipping, stability, segregation and labeling ¹⁴¹.
Process controls. The process should be controlled through written procedures, a quality control plan and documented review/approval responsibilities, with identification of critical process parameters and critical quality attributes to ensure consistent safety, purity and potency ¹⁴⁸¹⁰⁰.
Release testing and specifications. FDA expects specifications with acceptable ranges and lot/dose release testing, presented with test methods, acceptance criteria and, where appropriate, sensitivity/specificity in tabular form ¹³⁶¹³⁸¹⁰⁰. Product testing should assess identity, purity (including endotoxin), viability, potency and microbiological safety ¹⁰⁰.
Identity. Cellular product identity should use phenotypic and/or biochemical assays that distinguish the specified cells and assess heterogeneity, and identity should be among the predefined CQAs demonstrated by process control at licensure ¹³⁶¹⁰⁴¹⁰⁹.
Purity and residual impurities. Purity testing should address contaminating cells and residual process-related impurities (including endotoxin), and reagents/materials should be characterized because they can introduce adventitious agents and affect purity and potency ⁹⁹¹⁰⁰.
Viability. Cell viability should be evaluated, including after cryopreservation and after thaw/reconstitution, which is central for a cryopreserved off-the-shelf allogeneic product ⁹⁹¹⁰².
Safety testing. Microbiological testing should include sterility, mycoplasma and adventitious viral agent testing; for allogeneic cell-based products, safety testing should follow a risk analysis that considers expansion potential, reagents, and the number of subjects exposed ¹⁰⁰¹⁴⁵¹⁴⁷.

Potency

FDA expects a science- and risk-based potency assurance strategy rather than reliance on a single assay: potency risk is reduced through manufacturing design/control, material control, in-process testing and lot-release potency assays, so each released lot has the specific ability to achieve the intended therapeutic effect ⁵¹⁵⁹. Potency assays should be quantitative with adequate precision to distinguish sufficiently active from sub-potent product, and should be tied to the product's mechanism of action and potency-related CQAs ⁵⁶⁵¹.

Stage-appropriate and progressive. Potency measurement should develop incrementally across the program, starting from limited or surrogate measures early and maturing toward validated assays for later-phase and licensure use, with timely FDA discussion as assays are designed and validated ⁵²⁵⁹⁵¹.
Assay matrix. Many CGT products use multiple complementary potency assays; the current potency-assurance guidance supersedes the earlier 2011 "assay matrix" guidance and frames a comprehensive approach ⁵¹.
Short shelf-life products. Where there is insufficient time for a bioassay before release, one or more physicochemical potency assays can be used for lot release with sufficient in-process testing, with potency bioassays started immediately after manufacture and reviewed post-release ⁴⁹.

Comparability

Allogeneic iPSC platforms are built for iterative scale-up and process change, so lifecycle comparability is a recurring review issue. FDA's expectation is a risk-based, case-by-case demonstration, with the extent of study scaled to the nature of the change, the product, and the sensitivity of the analytical methods to detect differences ⁶⁹⁶⁵⁷⁵.

Analytical comparability. A side-by-side comparison of pre- and post-change material across relevant product quality attributes, using a sufficient number of lots and stability data as appropriate; limited data may suffice for low-risk minor changes to investigational products ⁶⁹⁷⁹.
Bridging. When analytical methods change or reference/comparator materials are involved, a risk assessment should determine the extent of bridging, which may range from partial to full revalidation plus comparative analysis of representative samples and reference material (consistent with ICH Q14) ⁸³⁹⁰.
Comparability protocols. A prospectively written comparability protocol describing tests, studies, procedures and acceptance criteria can be submitted in an original application or prior-approval supplement and, if approved, can support a reduced reporting category for the planned change ⁸⁴⁸⁸.
Quantitative endpoints. For gene therapy vector-related comparability, FDA recommends a quantitative potency assay as part of the comparability package ⁶⁰.

IND/BLA precedent and where the gaps are

The licensed-biologics record does not yet contain an approved allogeneic iPSC-derived cell therapy; the nearest allogeneic cell precedent identified is TREGZI (BLA 125868), an allogeneic HSPC/T-cell product whose review discusses stem-cell purification by phenotype but does not address iPSC-specific tumorigenicity, banking or CMC and is not iPSC-derived ⁷⁴. Accordingly, the operative "precedent" for iPSC programs is the accumulated IND-stage guidance framework above rather than a marketed product's approved specifications.

Two areas remain genuinely product-specific and are the most valuable to confirm directly with CBER for a given program: the acceptance limit and validated assay strategy for residual undifferentiated pluripotent cells in a differentiated product (not fixed by current guidance) ⁹⁵, and the precise tumorigenicity package for a differentiated, allogeneic, sometimes genome-edited final product, where the interplay of WGS, in vivo studies and comparability to previously tested cells is decided case by case ⁹⁶¹⁵⁷. These are natural next questions to bring to a Type B or INTERACT meeting, and the kind of program-specific analysis worth running against the guidance corpus directly.